^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600E + MSI-H

    i
    Other names: MSI-H, Microsatellite instability - high, dMMR, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    3ms
    A Case of Appendiceal Carcinoma with BRAF V600E Mutation and Microsatellite Instability-High (PubMed, Gan To Kagaku Ryoho)
    She received 8 courses of CapeOX as adjuvant chemotherapy and no recurrence was noted 12 months following the surgery. The establishment of standard treatment strategies including surgery, chemotherapy, and immunotherapy for carcinoma of the appendix with BRAF V600E mutation and/or MSI-H is needed.
    Journal • Microsatellite instability • MSi-H Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF V600E + MSI-H
    1year
    Advanced Appendiceal Cancer with Systematic Metastasis without Gastrointestinal Symptoms Found by Subcutaneous Tumor. (PubMed, Intern Med)
    Chemotherapy was administered, and she is currently still alive and undergoing chemotherapy. We describe a rare case of advanced appendiceal cancer without gastrointestinal symptoms diagnosed due to cutaneous metastasis.
    Journal • MSi-H Biomarker • Metastases
    |
    MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF V600E + MSI-H
    over1year
    SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab vs pembrolizumab alone for first-line treatment of BRAF V600E–mutant microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). (ASCO-GI 2023)
    Enrollment started in July 2022. Clinical trial information: NCT05217446.
    Clinical • P2 data • Mismatch repair • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • RAS mutation • BRAF V600E + MSI-H • MSI-H/dMMR + BRAF V600E
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib)
    almost2years
    SEAMARK: Randomized phase 2 study of pembrolizumab + encorafenib + cetuximab versus pembrolizumab alone for first-line treatment of BRAF V600E-mutant and microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC). (ASCO 2022)
    Secondary endpoints include safety and tolerability, overall survival, objective response rate, duration of response, and quality of life. Enrollment will begin in April 2022.
    Clinical • P2 data • Mismatch repair • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF V600E + MSI-H • MSI-H/dMMR + BRAF V600E
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • Braftovi (encorafenib)